{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-015132","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2026-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.796242+00:00","generated_at":"2026-05-15T07:38:23.896838+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivos Therapeutics raises ~$2.39M in PIPE financing from V-Co 3; includes conversion of $1.4M bridge note","bullets":["Sold 1,353,625 shares, pre-funded warrant for 429,957 shares, and Series A/B warrants for 1,783,582 each at $1.34 per unit.","Cash proceeds of $850,000; $1,400,000 bridge note converted; gross proceeds $2,390,000.","Series A/B warrants exercisable at $1.09 (2 and 5 year terms); pre-funded warrant exercisable at $0.0001.","Company must file resale registration statement within 45 days and use best efforts for effectiveness within 90 days.","Net proceeds to be used for general working capital purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-015132","json":"https://secwatch.observer/filing/0001493152-26-015132.json","markdown":"https://secwatch.observer/filing/0001493152-26-015132.md","text":"https://secwatch.observer/filing/0001493152-26-015132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:38:23.896838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f88cf4009070e3eea0a98712e1d566dc0f97f338","claim":"Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with V-Co Investors 3 LLC valued at $850,000 cash proceeds; $1,400,000 conversion of bridge note; total purchase price $1.34 per share (effective 2026-03-31).","evidence_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001493152-26-026890","ticker":"XWIN","company_name":"XMax Inc.","filed_at":"2026-06-02T20:30:36+00:00","headline":"XMax raises $3.6M via private placement of 486,500 shares at $7.347/share","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026890","json":"https://secwatch.observer/filing/0001493152-26-026890.json","markdown":"https://secwatch.observer/filing/0001493152-26-026890.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/0001493152-26-026890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","comparable_excerpt":"On May 28, 2026, XMax Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ Agreements ”) with certain non-U.S. investors identified on the signature pages thereto (the “ Purchasers ”), pursuant to which the Company agreed to sell to the Purchasers in a private placement for a total of 486,500 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $7.347 per share for an aggregate offering price of $3,574,315.50 (the “ Private Placement ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1473334/000149315226026890/0001493152-26-026890-index.htm"}},{"accession":"0001193125-26-251994","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-01T23:13:20+00:00","headline":"Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251994","json":"https://secwatch.observer/filing/0001193125-26-251994.json","markdown":"https://secwatch.observer/filing/0001193125-26-251994.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/d105562d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","comparable_excerpt":"On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","comparable_excerpt":"A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001683168-26-004423","ticker":"CITR","company_name":"CitroTech Inc.","filed_at":"2026-06-01T20:15:28+00:00","headline":"CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004423","json":"https://secwatch.observer/filing/0001683168-26-004423.json","markdown":"https://secwatch.observer/filing/0001683168-26-004423.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/citro_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","comparable_excerpt":"On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm"}},{"accession":"0001829126-26-004879","ticker":"SAGU","company_name":"Shreya Acquisition Group","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004879","json":"https://secwatch.observer/filing/0001829126-26-004879.json","markdown":"https://secwatch.observer/filing/0001829126-26-004879.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/shreyaacq_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","comparable_excerpt":"Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm"}},{"accession":"0001104659-26-057976","ticker":"XRN","company_name":"Chiron Real Estate Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Chiron Real Estate enters $100M preferred equity deal with Maewyn XRN LP","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057976","json":"https://secwatch.observer/filing/0001104659-26-057976.json","markdown":"https://secwatch.observer/filing/0001104659-26-057976.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/0001104659-26-057976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/tm2613926d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","comparable_excerpt":"In connection with the Private Placement, on May 6, 2026, the Company and the Purchasers entered an Investor Rights Agreement.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/0001104659-26-057976-index.htm"}},{"accession":"0001493152-26-021863","ticker":"AIM","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"AIM ImmunoTech expects ~$4.2M gross from warrant inducement at $0.48/share; new warrants at $0.60","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-021863","json":"https://secwatch.observer/filing/0001493152-26-021863.json","markdown":"https://secwatch.observer/filing/0001493152-26-021863.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226021863/0001493152-26-021863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226021863/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","comparable_excerpt":"On May 7, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with holders (the “Holders”) of (i) Class A and Class B common stock purchase warrants issued on May 31, 2024","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226021863/0001493152-26-021863-index.htm"}},{"accession":"0001493152-26-022034","ticker":"AREB","company_name":"AMERICAN REBEL HOLDINGS INC","filed_at":"2026-05-08T23:59:59+00:00","headline":"American Rebel exchanges $1.77M preferred & note for ~5.97M common shares to Streeterville","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022034","json":"https://secwatch.observer/filing/0001493152-26-022034.json","markdown":"https://secwatch.observer/filing/0001493152-26-022034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/0001493152-26-022034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm","comparable_excerpt":"Streeterville\nSeries E Preferred Exchange Agreements On\nApril 30, 2026, the Company entered into three Exchange Agreements (the “Exchanges”) with Streeterville.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/0001493152-26-022034-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}